SG Americas Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

SG Americas Securities’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-55,100	Closed	-$297K	–	3750
2025 Q4	$297K	Buy	+55,100	New	+$23.7M	﹤0.01%	2760
2024 Q4	–	Sell	-2,400	Closed	-$178K	–	3662
2024 Q3	$178K	Buy	2,400 +900	+60%	+$432K	﹤0.01%	2598
2024 Q2	$138K	Sell	1,500 -7,100	-83%	-$3.08M	﹤0.01%	2372
2024 Q1	$465K	Sell	8,600 -45,400	-84%	-$19.2M	﹤0.01%	1467
2023 Q4	$1.26M	Sell	54,000 -5,600	-9%	-$2.07M	0.01%	899
2023 Q3	$593K	Buy	59,600 +54,600	+1,092%	+$19.1M	0.01%	1639
2023 Q2	$156K	Sell	5,000 -83,000	-94%	-$28M	﹤0.01%	1901
2023 Q1	$1.17M	Buy	88,000 +78,000	+780%	+$23.4M	0.01%	1038
2022 Q4	$6K	Buy	10,000 +2,000	+25%	+$610K	﹤0.01%	2986
2022 Q3	$281K	Sell	8,000 -5,000	-38%	-$1.44M	﹤0.01%	2042
2022 Q2	$482K	Sell	13,000 -87,500	-87%	-$23.4M	0.01%	1993
2022 Q1	$3.03M	Buy	100,500 +85,500	+570%	+$20.3M	0.02%	661
2021 Q4	$692K	Buy	+15,000	New	+$2.92M	﹤0.01%	1913
2020 Q4	–	Sell	-40,000	Closed	-$56K	–	3492
2020 Q3	$56K	Buy	+40,000	New	+$11M	﹤0.01%	2513
2016 Q4	–	Sell	-12,000	Closed	-$11K	–	3492
2016 Q3	$11K	Hold	12,000	–	–	﹤0.01%	3276
2016 Q2	$17K	Hold	12,000	–	–	﹤0.01%	2516
2016 Q1	$26K	Hold	12,000	–	–	﹤0.01%	2821
2015 Q4	$263K	Buy	+12,000	New	+$1.45M	﹤0.01%	1959
2015 Q3	–	Sell	-12,000	Closed	-$290K	–	2722
2015 Q2	$290K	Hold	12,000	–	–	﹤0.01%	1799
2015 Q1	$276K	Buy	+12,000	New	+$1.44M	﹤0.01%	1728

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

SG Americas Securities's VRTX Position: Q1 2026 in Review

SG Americas Securities reduced its Vertex Pharmaceuticals (VRTX) stake by 51% in Q1 2026, selling an estimated $27.5M and leaving 56,982 shares worth $25.4M. The position accounts for 0.03% of the portfolio, ranked #459.

SG Americas Securities first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $52.5M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

SG Americas Securities held 56,982 shares of Vertex Pharmaceuticals worth $25.4M as of Q1 2026.
SG Americas Securities sold 58,917 Vertex Pharmaceuticals shares in Q1 2026, an estimated $27.5M.
Vertex Pharmaceuticals made up 0.03% of SG Americas Securities's portfolio in Q1 2026, its #459 holding.
SG Americas Securities first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
SG Americas Securities's Vertex Pharmaceuticals position peaked at $52.5M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.